Perbak Capital Partners LLP Purchases New Shares in IQVIA Holdings Inc. $IQV

Key Points

• Perbak Capital Partners LLP has acquired a new stake in IQVIA Holdings Inc., purchasing 1,545 shares valued at approximately $272,000.
• Recent institutional activity includes significant stakes being added by Pacer Advisors Inc. and JPMorgan Chase & Co., with Pacer Advisors increasing its holdings by 5,036.1%, now owning shares worth $153.68 million.
• IQVIA reported a quarterly earnings per share (EPS) of $2.81, exceeding analysts' expectations, with a 5.3% increase in revenue compared to the previous year.

Perbak Capital Partners LLP bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,545 shares of the medical research company's stock, valued at approximately $272,000.

Other institutional investors also recently bought and sold shares of the company. American National Bank & Trust purchased a new stake in shares of IQVIA in the 1st quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC raised its stake in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC purchased a new stake in shares of IQVIA in the 1st quarter valued at approximately $33,000. Finally, ST Germain D J Co. Inc. raised its stake in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Stock Down 0.1%

NYSE IQV traded down $0.24 on Monday, hitting $187.45. 379,367 shares of the stock were exchanged, compared to its average volume of 1,915,026. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $248.03. The company has a market cap of $31.87 billion, a PE ratio of 27.13, a PEG ratio of 2.06 and a beta of 1.32. The company has a 50-day moving average price of $179.88 and a 200-day moving average price of $167.23.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter in the previous year, the business posted $2.64 EPS. The firm's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on IQV. Citigroup reissued a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Truist Financial boosted their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Barclays boosted their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Finally, Evercore ISI lifted their price objective on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $229.86.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.